Get Integrated Data for Your Specialty and Interest Aresa
Category Select :
Items 181 ~ 200 of 25664, Page 10 of 1284
181. First analysis of ''pre-registered'' studies shows sharp rise in null findings - 10/24/2018
 Nature News by Matthew Warren
  Logging hypotheses and protocols before performing research seems to work as intended: to reduce publication bias for positive results.
182. Leading cancer research charity takes tough stance on bullying - 10/24/2018
 Nature News by Holly Else
  Cancer Research UK will be able to revoke grants if researchers and institutions do not abide by its new behaviour policy.
183. HH Pope Francis and WHO Director-General: Health is a right and not a privilege - 10/23/2018
 World Health Organization (WHO)
  The Director-General of WHO, Dr Tedros Adhanom Ghebreyesus, has met with His Holiness Pope Francis to discuss ways to ensure that all people can obtain the healthcare they need, whoever they are, wherever they live.
184. Medtronic Receives FDA Approval for Valiant Navion(TM) Thoracic Stent Graft System - 10/23/2018
  (GLOBE NEWSWIRE via COMTEX) --Next-Generation Thoracic Endovascular Repair (TEVAR) Device Expands Applicability to Broader Range of Patients
185. 3 keys to giving physicians more face time with patients - 10/23/2018
 American Medical Association (AMA) News by Sara Berg
  Learn about a team-based primary care model that cuts patient wait times, gives doctors more time delivering care and raises job satisfaction.
186. Small practice, less doctor burnout? 4 reasons that may be - 10/23/2018
 American Medical Association (AMA) News by Tanya Albert Henry
  Autonomy, deeper patient relationships among the reasons physicians at small offices may report less burnout.
187. European Medicines Agency Adopts Positive Opinion for Mercks KEYTRUDA (pembrolizumab) as Adjuvant Therapy in Melanoma - 10/22/2018
  Opinion Granted Based on Significant Recurrence-Free Survival Benefit Demonstrated with KEYTRUDA in Pivotal Phase 3 EORTC1325/KEYNOTE-054 Trial Marks First Positive CHMP Opinion for KEYTRUDA in an Adjuvant Setting
188. Merck"s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer - 10/22/2018
  Survival Benefit Observed with KEYTRUDA Monotherapy in Patients Whose Tumors Expressed PD-L1 with CPS20 and CPS1 and in Total Patient Population for KEYTRUDA in Combination with Chemotherapy KEYTRUDA is the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit as First-Line Therapy for Head and Neck Cancer that has Recurred or Metastasized Results from Pivotal Phase 3 KEYNOTE-048 Trial Presented Today at the ESMO 2018 Congress during the Presidential Symposium
189. Effect of Protocolized Weaning With Early Extubation to Noninvasive Ventilation vs Invasive Weaning on Time to Liberation From Mechanical Ventilation Among Patients With Respiratory Failure - 10/22/2018
 JAMA. Published online October 22, 2018. doi:10.1001/jama.2018.13763
  This randomized trial compares the effects of protocolized weaning via early extubation to noninvasive ventilation vs standard weaning from invasive ventilation on time to liberation from mechanical ventilation among adults with respiratory failure ready to wean but with an unsuccessful spontaneous breathing trial.
190. British universities set up European outposts as Brexit looms - 10/22/2018
 Nature News by Quirin Schiermeier
  Establishing partner institutions in Europe might allow UK researchers to keep full access to EU funds.
191. When fathers exercise, their future offspring may benefit, mouse study suggests - 10/22/2018
 Science: Health by Mitch Leslie
  This exercising mouse is helping itself and its offspring, a new study suggests.
192. SOLO-1 Phase 3 Trial Demonstrates LYNPARZA (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer - 10/21/2018
  60 Percent of Patients Receiving LYNPARZA Remained Progression-Free at Three Years Compared to 27 Percent on Placebo Following Platinum-Based Chemotherapy YNPARZA Is the Only PARP Inhibitor to Demonstrate an Improvement in Progression-Free Survival in First-Line Maintenance Treatment for Newly-Diagnosed, Advanced Ovarian Cancer
193. Medtronic Co-Founder Earl Bakken Passes Away at Age 94 - 10/21/2018
  (GLOBE NEWSWIRE via COMTEX) --DUBLIN - October 21, 2018 - Medtronic plc (NYSE:MDT) announced today that its co-founder, Earl E. Bakken, passed away peacefully on October 21, 2018 at his home on Kiholo Bay on the Big Island of Hawaii. He was 94 years old.
194. Giant study links DNA variants to same-sex behavior - 10/20/2018
 Science: Biology, Brain & Behavior News by Michael Price
  A study of hundreds of thousands of people uncovered four genetic variants that were more common in people who reported at least one instance of same-sex sexual behavior.
195. Merck"s KEYTRUDA (pembrolizumab) Showed a Complete Response Rate of Nearly 40 Percent in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Standard of Care - 10/20/2018
  First-Time Data for KEYTRUDA in NMIBC from Phase 2 KEYNOTE-057 Trial to be Presented at ESMO 2018 Congress
196. First Presentation of Early Data for Mercks Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress - 10/20/2018
  New Clinical Findings Involving STING Agonist as Monotherapy and in Combination with an Anti-PD-1 Therapy
197. Abbott''s HeartMate 3 Heart Pump Now FDA Approved for Advanced Heart Failure Patients Not Eligible for a Heart Transplant - 10/19/2018
  ABBOTT PARK, Ill., Oct. 19, 2018 /PRNewswire/ Abbott (NYSE: ABT) announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S. Food and Drug Administration (FDA) approval as a destination therapy for people living with advanced heart failure. With the approval, physicians can now offer the HeartMate 3 system to patients not eligible for a transplant who will live with their device for the rest of their lives.
198. Virus detectives test whole-body scans in search of HIV hiding places - 10/19/2018
 Nature News by Sara Reardon
  To prevent the virus from rebounding after drug therapy, researchers must first map where it lurks in the body.
199. Hospitals could save $25.4B annually in supply chain costs, study finds - 10/19/2018
 Becker's Hospital Review by Kelly Gooch
  The study of 2,300 U.S. hospitals found facilities could save an average of 17.7 percent or $11 million annually per hospital on supply chain products and related operations, processes and procedures if they performed in the top 25 percent of hospitals nationwide for supply chain budget efficiency.
200. Nation"s Medical Specialists Demand Immediate End to Prior Authorization Abuse - 10/19/2018
 American Academy of Ophthalmology
  Physicians, patients and Congress agree: Medicare Advantage plans must stop needless delays in medically necessary care
<<  <  [1]  [2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  [10>  >>

Copyright ~2018 by Medisurf. All Rights Reserved Terms of Service Privacy Email :